Janux Therapeutics

Update in progress

JANX (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies using its TRACTr, TRACIr and Adaptive Immune Response Modulator platforms to treat cancer and Autoimmune diseases. Lead assets include JANX007 (PSMA-TRACTr) in Phase 1 for metastatic castration-resistant prostate cancer and tumor vasculature; JANX008 (EGFR-TRACTr) in Phase 1 for several solid tumors; JANX011 (CD19 ARM) in Phase 1 for autoimmune disease. Partners include Merck and Bristol Myers Squibb. Founded 2017, based in San Diego.

Company score

Sentiment: 0.12; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.01; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.09; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive